Adult patients w/ chronic heart failure to reduce the risk of CV death & hospitalization due to heart failure in place of ACE inhibitor or angiotensin II receptor blocker (ARB). Benefits are most clear in patients w/ LVEF below normal.
Adult 100 mg bid, doubled up to 200 mg bid every 2-4 wk as tolerated. Patient not currently taking ACE inhibitor or ARB Initially 50 mg bid. Severe renal & moderate hepatic impairment Initially 50 mg bid.
View Entresto overdosage for action to be taken in the event of an overdose.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Not to be administered until 36 hr after discontinuation of ACE inhibitor therapy. Known history of angioedema related to previous ACE inhibitor or ARB therapy. Hereditary angioedema. Concomitant use w/ ACE inhibitors & aliskiren in patients w/ type 2 diabetes. Pregnancy.
Discontinue use if angioedema occurs. Temporarily discontinue use if hypotension persists. Down-titration if clinically significant decreased in renal function develops. Angioedema associated w/ laryngeal edema. Increased risk of hyperkalemia. Patients w/ bilateral or unilateral renal artery stenosis. Vol-depleted patient. Black patients. Correct Na &/or vol depletion prior to initiation of treatment. Monitor serum K in patients w/ risk factors eg, DM, hypoaldosteronism, severe renal impairment, receiving high K diet. Monitor renal function in patients w/ renal artery stenosis. Not to co-administer w/ direct renin inhibitors (eg, aliskiren), ARB. Concomitant use w/ K-sparing diuretics, K supplements. Severe renal & hepatic impairment. Women of childbearing potential should use contraception during treatment & for 1 wk after last dose. Not to be used during pregnancy. Not recommended during lactation. Ped patient <18 yr.
C09DX04 - valsartan and sacubitril ; Belongs to the class of angiotensin II receptor blockers (ARBs), other combinations. Used in the treatment of cardiovascular disease.
Sign Out
